Molecular Partners (ADR) (MOLN)
Develops DARPin cancer therapies, including Radio-DARPins and immune-cell engagers.
$4.24
Pre-market+0.03 (+0.65%)
At close$4.21(−1.75%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions4 holders · as of Mar 31, 2026 | 9.57% | 3.59M ADS | |
| Strategic holders1 holder · as of Jul 17, 2025 | 5.72% | 2.14M ADS | |
| Otherremainder | 84.71% | 31.78M ADS |
37.51M ADS as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count is from the company's Dec 2024 annual report; nothing newer is on file here.
Institutions13F, as of Mar 31, 2026
4 holders · 3.59M shares · 0 new positions · 1 increased · 0 reduced · 2 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 2.22M | 5.92% | 0 | May 15, 2026 |
| BVF Inc/IL | 1.35M | 3.61% | 0 | May 15, 2026 |
| Smartharvest Portfolios, LLC | 15.5K | 0.04% | +3.2K | Apr 21, 2026 |
| Morgan Stanley | 367 | 0.00% | 0 | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 10.60% | 4.28M | 13G | May 2, 2025 ↗ |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 5.80% | 2.14M | 13G | Jul 17, 2025 ↗ |
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.